Burkhard Vangerow

2.4k total citations · 1 hit paper
14 papers, 1.1k citations indexed

About

Burkhard Vangerow is a scholar working on Surgery, Oncology and Epidemiology. According to data from OpenAlex, Burkhard Vangerow has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 5 papers in Oncology and 3 papers in Epidemiology. Recurrent topics in Burkhard Vangerow's work include Cancer Immunotherapy and Biomarkers (4 papers), Sepsis Diagnosis and Treatment (3 papers) and Hemodynamic Monitoring and Therapy (3 papers). Burkhard Vangerow is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Sepsis Diagnosis and Treatment (3 papers) and Hemodynamic Monitoring and Therapy (3 papers). Burkhard Vangerow collaborates with scholars based in United States, Germany and United Kingdom. Burkhard Vangerow's co-authors include Jonathan Janes, Jyrki Tenhunen, Antonio Artigas, Bruce Thompson, Jean-François Dhainaut, Vivian P. Thompson, Didier Payen, Bengt Gårdlund, Ivor S. Douglas and Hussein R. Al‐Khalidi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Burkhard Vangerow

14 papers receiving 1.1k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drotrecogin Alfa (Activated) in Adults with Septic Shock

2012 877 citations V. Marco Ranieri, Bruce Thompson et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Burkhard Vangerow United States	9	626	263	259	246	155	14	1.1k
Jennifer A. Muszynski United States	18	415 0.7×	312 1.2×	152 0.6×	156 0.6×	170 1.1×	58	1.1k
Barbara G. Utterback United States	13	937 1.5×	334 1.3×	168 0.6×	208 0.8×	186 1.2×	21	1.5k
Pierre Singer Israel	5	693 1.1×	276 1.0×	137 0.5×	187 0.8×	151 1.0×	16	1.0k
Pierre Perez France	15	708 1.1×	289 1.1×	249 1.0×	310 1.3×	338 2.2×	32	1.5k
Anthony Dal Nogare United States	7	609 1.0×	282 1.1×	380 1.5×	202 0.8×	457 2.9×	7	1.4k
István Pénzes Hungary	8	710 1.1×	286 1.1×	160 0.6×	161 0.7×	218 1.4×	22	1.2k
F. Schindel Germany	10	717 1.1×	293 1.1×	158 0.6×	171 0.7×	135 0.9×	13	1.2k
Geoffrey L. Allen United States	19	946 1.5×	190 0.7×	392 1.5×	182 0.7×	254 1.6×	31	1.5k
Taekyu Hwang United States	7	1.1k 1.7×	399 1.5×	274 1.1×	345 1.4×	264 1.7×	8	2.1k
Marie Monaco United States	10	672 1.1×	182 0.7×	336 1.3×	119 0.5×	154 1.0×	10	1.2k

Countries citing papers authored by Burkhard Vangerow

Since Specialization

Citations

This map shows the geographic impact of Burkhard Vangerow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Burkhard Vangerow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Burkhard Vangerow more than expected).

Fields of papers citing papers by Burkhard Vangerow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Burkhard Vangerow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Burkhard Vangerow. The network helps show where Burkhard Vangerow may publish in the future.

Co-authorship network of co-authors of Burkhard Vangerow

This figure shows the co-authorship network connecting the top 25 collaborators of Burkhard Vangerow. A scholar is included among the top collaborators of Burkhard Vangerow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Burkhard Vangerow. Burkhard Vangerow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Patnaik, Amita, Timothy A. Yap, Hyun Cheol Chung, et al.. (2020). Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. Clinical Cancer Research. 27(5). 1267–1277. 31 indexed citations

O’Hara, Mark H., Wells A. Messersmith, Hedy L. Kindler, et al.. (2020). Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. SHILAP Revista de lepidopterología. 6(1). 21–31. 37 indexed citations

Hellmann, Matthew D., Toshio Shimizu, Toshihiko Doi, et al.. (2019). A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). TPS2654–TPS2654. 2 indexed citations

Power, Thomas P., Xuehua Ke, Zhenxiang Zhao, et al.. (2018). Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease. Vascular Health and Risk Management. Volume 14. 23–36. 6 indexed citations

Patnaik, Amita, Yung‐Jue Bang, Hyun Cheol Chung, et al.. (2018). Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents. Cancer Research. 78(13_Supplement). CT018–CT018. 2 indexed citations

Nicholls, Stephen J., A. Michael Lincoff, Philip J. Barter, et al.. (2015). Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. American Heart Journal. 170(6). 1061–1069. 67 indexed citations

Ranieri, V. Marco, Bruce Thompson, Philip S. Barie, et al.. (2012). Drotrecogin Alfa (Activated) in Adults with Septic Shock. New England Journal of Medicine. 366(22). 2055–2064. 877 indexed citations breakdown →

Shorr, Andrew F., Jonathan Janes, Antonio Artigas, et al.. (2010). Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). Critical Care. 14(6). R229–R229. 14 indexed citations

Vangerow, Burkhard, Andrew F. Shorr, Duncan Wyncoll, et al.. (2007). The protein C pathway: implications for the design of the RESPOND study. Critical Care. 11(Suppl 5). S4–S4. 13 indexed citations

10.

Lorenz, Ralf, Burkhard Vangerow, Martin Loss, et al.. (2002). C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation. Transplantation. 73(5). 688–694. 28 indexed citations

11.

Przemeck, Michael, Burkhard Vangerow, Martin Loss, et al.. (2001). HEMODYNAMIC CONSEQUENCES OF PORCINE KIDNEY XENOGRAFT REPERFUSION IN CYNOMOLGUS MONKEYS1,2. Transplantation. 71(11). 1512–1514. 7 indexed citations

12.

Vangerow, Burkhard, et al.. (2001). Effects of C1 inhibitor and r-SP-C surfactant on oxygenation and histology in rats with lavage-induced acute lung injury. Intensive Care Medicine. 27(9). 1526–1531. 7 indexed citations

13.

Vangerow, Burkhard, Ralf Lorenz, Martin Loss, et al.. (2001). C1‐Inhibitor for treatment of acute vascular xenograft rejection in cynomolgus recipients of h‐DAF transgenic porcine kidneys. Xenotransplantation. 8(4). 266–272. 33 indexed citations

14.

Marx, Gernot, et al.. (2000). Cardiac Output Measurement by Arterial Thermodilution in Piglets. Anesthesia & Analgesia. 90(1). 57–58. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact